Cyclotron production of 99m Tc is a promising route to supply 99m Tc radiopharmaceuticals. Higher 99m Tc yields can be obtained with medium-energy cyclotrons in comparison to those dedicated to PET isotope production. To take advantage of this capability, evaluation of the radioisotopic purity of 99m Tc produced at medium energy (20)(21)(22)(23)(24) and its impact on image quality and dosimetry was required. Methods: Thick 100 Mo (99.03% and 99.815%) targets were irradiated with incident energies of 20, 22, and 24 MeV for 2 or 6 h. The targets were processed to recover an effective thickness corresponding to approximately 5-MeV energy loss, and the resulting sodium pertechnetate 99m Tc was assayed for chemical, radiochemical, and radionuclidic purity. Radioisotopic content in final formulation was quantified using g-ray spectrometry. The internal radiation dose for 99m Tc-pertechnetate was calculated on the basis of experimentally measured values and biokinetic data in humans. Planar and SPECT imaging were performed using thin capillary and water-filled Jaszczak phantoms. Results: Extracted sodium pertechnetate 99m Tc met all provisional quality standards. The formulated solution for injection had a pH of 5.0−5.5, contained greater than 98% of radioactivity in the form of pertechnetate ion, and was stable for at least 24 h after formulation. Radioisotopic purity of 99m Tc produced with 99.03% enriched 100 Mo was greater than 99.0% decay corrected to the end of bombardment (EOB). The radioisotopic purity of 99m Tc produced with 99.815% enriched 100 Mo was 99.98% or greater (decay corrected to the EOB). The estimated dose increase relative to 99m Tc without any radionuclidic impurities was below 10% for sodium pertechnetate 99m Tc produced from 99.03% 100 Mo if injected up to 6 h after the EOB. For 99.815% 100 Mo, the increase in effective dose was less than 2% at 6 h after the EOB and less than 4% at 15 h after the EOB when the target was irradiated at an incident energy of 24 MeV. Image spatial resolution and contrast with cyclotron-produced 99m Tc were equivalent to those obtained with 99m Tc eluted from a conventional generator. Conclusion: Clinical-grade sodium pertechnetate 99m Tc was produced with a cyclotron at medium energies. Quality control procedures and release specifications were drafted as part of a clinical trial application that received approval from Health Canada. The results of this work are intended to contribute to establishing a regulatory framework for using cyclotron-produced 99m Tc in routine clinical practice. The radioisotope 99m Tc remains indispensable in nuclear imaging. 99m Tc is usually obtained from generators containing the mother isotope, 99 Mo, which in turn is made from highly enriched 235 U ($20%, typically 93%) in nuclear reactors. 99m Tc is eluted in the form of sodium pertechnetate and can be used as is or as the starting material for other 99m Tc radiopharmaceuticals used in a variety of diagnostic applications. Cyclotron production of 99m Tc could be a viable alternativ...
Silicon-containing prosthetic groups have been conjugated to peptides to allow for a single-step labeling with (18)F radioisotope. The fairly lipophilic di-tert-butylphenylsilane building block contributes unfavorably to the pharmacokinetic profile of bombesin conjugates. In this article, theoretical and experimental studies toward the development of more hydrophilic silicon-based building blocks are presented. Density functional theory calculations were used to predict the hydrolytic stability of di-tert-butylfluorosilanes 2-23 with the aim to improve the in vivo properties of (18)F-labeled silicon-containing biomolecules. As a further step toward improving the pharmacokinetic profile, hydrophilic linkers were introduced between the lipophilic di-tert-butylphenylsilane building block and the bombesin congeners. Increased tumor uptake was shown with two of these peptides in xenograft-bearing mice using positron emission tomography and biodistribution studies. The introduction of a hydrophilic linker is thus a viable approach to improve the tumor uptake of (18)F-labeled silicon-bombesin conjugates.
The activity of matrix metalloproteinases (MMPs) is elevated locally under many pathological conditions. Gelatinases MMP2 and MMP9 are of particular interest because of their implication in angiogenesis, cancer cell proliferation and metastasis, and atherosclerotic plaque rupture. The aim of this study was to identify and develop a selective gelatinase inhibitor for imaging active MMP2/MMP9 in vivo. We synthesized a series of N-sulfonylamino acid derivatives with low to high nanomolar inhibitory potencies. (R)-2-(4-(4-Fluorobenzamido)phenylsulfonamido)-3-(1H-indol-3-yl)propanoic acid (7) exhibited the best in vitro binding properties: MMP2 IC50 = 1.8 nM, MMP9 IC50 = 7.2 nM. Radiolabeling of 7 with no carrier added (18)F-radioisotope was accomplished starting from iodonium salts as precursors. The radiochemical yield strongly depended on the iodonium counteranion (ClO4(-) > Br(-) > TFA(-) > tosylate). (18)F-7 was obtained in up to 20% radiochemical yield (decay corrected), high radiochemical purity, and >90 GBq/μmol specific radioactivity. The radiolabeled compound showed excellent stability in vitro and in mice in vivo.
Cervical
cancer is the fourth most common malignancy among women.
Compared to other types of cancer, therapeutic agents can be administrated
locally at the mucosal vaginal membrane. Thermosensitive gels have
been developed over the years for contraception or for the treatment
of bacterial, fungal, and sexually transmitted infections. These formulations
often carry therapeutic nanoparticles and are now being considered
in the arsenal of tools for oncology. They can also be three-dimensionally
(3D) printed for a better geometrical adjustment to the anatomy of
the patient, thus enhancing the local delivery treatment. In this
study, a localized delivery system composed of a Pluronic F127-alginate
hydrogel with efficient nanoparticle (NP) release properties was prepared
for intravaginal application procedures. The kinetics of hydrogel
degradation and its NP releasing properties were demonstrated with
ultrasmall gold nanoparticles (∼80% of encapsulated AuNPs released
in 48 h). The mucoadhesive properties of the hydrogel formulation
were assayed by the periodic acid/Schiff reagent staining, which revealed
that 19% of mucins were adsorbed on the gel’s surface. The
hydrogel formulation was tested for cytocompatibility in three cell
lines (HeLa, CRL 2616, and BT-474; no sign of cytotoxicity revealed).
The release of AuNPs from the hydrogel and their accumulation in vaginal
membranes were quantitatively measured in vitro/ex vivo with positron emission tomography, a highly sensitive
modality allowing real-time imaging of nanoparticle diffusion (lag
time to start of permeation of 3.3 h, 47% of AuNPs accumulated in
the mucosa after 42 h). Finally, the potential of the AuNP-containing
Pluronic F127-alginate hydrogel for 3D printing was demonstrated,
and the geometrical precision of the 3D printed systems was measured
by magnetic resonance imaging (<0.5 mm precision; deviation from
the design values <2.5%). In summary, this study demonstrates the
potential of Pluronic F127-alginate formulations for the topical administration
of NP-releasing gels applied to vaginal wall therapy. This technology
could open new possibilities for photothermal and radiosensitizing
oncology applications.
18F radiolabelling of peptides bearing two different prosthetic groups was successfully conducted in a continuous flow microfluidic device for the first time. Radiochemical yields were dependent on precursor concentration, reaction temperature and flow rate. The choice of leaving group had a dramatic influence on the reaction outcome. Rapid reaction optimization was possible.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.